ArticleTransboundary and emerging diseases2025
Development and Characterization of Monoclonal Antibodies Against VP3 Protein of Infectious Bursal Disease Virus.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Parameters of Hybridoma Cells: Methods of Evaluation and Biotechnological Relevance.Antibodies (Basel, Switzerland) · 2026Review
- Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review.Viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bursal disease virus (IBDV) causes an acute, highly contagious and immunosuppressive disease in 3-5-week-old chicken, called infectious bursal disease (IBD). Current vaccines targeting the hypervariable VP2 gene fail to provide cross-protection against different IBDV strains, necessitating the development of novel diagnostic and preventive strategies that explore other candidate genes to ensure immune efficacy. Here, VP3, a conserved nucleocapsid protein of IBDV, was selected for further analysis. A prokaryotic expression vector, pET-32a-IBDV-VP3, was constructed, followed by expression and purification of the recombinant protein. Following the intraperitoneal injection of recombinant proteins into the mice, eight monoclonal antibodies (mAbs) were identified by hybridoma cell fusion, clone purification, and immunological assays. Among the mAbs, mAb 19D8 effectively neutralized IBDV infection during viral attachment and penetration. Antigenic epitopes of mAb 19D8 were identified using alanine-scanning mutagenesis. Our results showed that four amino acids, F20, K21, T23, and E25, located on an α-helix of the VP3, were the key amino acids recognized by 19D8. Homologous and structural analyses revealed that these sites were highly conserved across different IBDV strains from diverse regions. These findings provide crucial insights into the antigenicity of VP3 and underscore the potential of VP3 as a target for the development of broad-spectrum diagnostic tools and cross-protection vaccines against IBDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.